Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.68 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22411503 | 0.82 | DRD2 (0.45) | DRD2ESR2ESR1DRD4DRD3 | |
| SCHEMBL8398996 | 0.81 | DRD2 (0.51) | DRD2ESR2ESR1SIGMAR1OPRM1 | |
| SCHEMBL12193959 | 0.81 | DRD2 (0.66) | DRD2SIGMAR1OPRM1MAPKAPK2 | |
| SCHEMBL4472985 | 0.81 | DRD2 (0.66) | DRD2SIGMAR1DRD4DRD3OPRM1 | |
| SCHEMBL578373 | 0.81 | DRD2 (0.66) | DRD2SIGMAR1DRD4DRD3OPRM1 | |
| SCHEMBL613058 | 0.81 | DRD2 (0.66) | DRD2SIGMAR1OPRM1KCNH2OPRD1 | |
| SCHEMBL187716 | 0.81 | DRD2 (1.00) | DRD2DRD4DRD3OPRM1OPRD1 | |
| SCHEMBL615480 | 0.81 | DRD2 (0.66) | DRD2SIGMAR1DRD4DRD3OPRM1 | |
| SCHEMBL306026 | 0.80 | DRD2 (0.64) | DRD2SIGMAR1OPRM1OPRD1CYP2D6 | |
| SCHEMBL21051570 | 0.79 | ESR2 (0.56) | DRD2ESR2ESR1DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| WO-2020186220-A1 | COMPOUNDS AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2020-09-17 | — | — | WO | disclosed |
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| CN-104031054-A | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARM INC | 2014-09-10 | — | — | CN | disclosed |
| CN-102388048-B | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer | ASTRAZENECA AB | 2014-07-30 | — | — | CN | disclosed |
| CN-1585772-B | chemokine receptor antagonists and methods and uses thereof | MILLENNIUM PHARM INC | 2014-06-04 | — | — | CN | disclosed |
| US-8653096-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| WO-1999064041-A9 | MULTIBINDING AGENTS THAT MODULATE NMDA RECEPTORS | ADVANCED MEDICINE INC (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1100519-A1 | MULTIBINDING AGENTS THAT MODULATE NMDA RECEPTORS | Advanced Medicine, Inc. (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-1097924-A1 | 4-hydroxy-4-phenylpiperidine derivatives having -opioid agonist activity and pharmaceuticals containing the same | SSP Co., Ltd. (JP) | 2001-05-09 | — | — | EP | disclosed |
| CN-1289336-A | Chemokine receptor antagonists and methods of use therefor | LEUKOSITE INC (US) | 2001-03-28 | — | — | CN | disclosed |
| WO-2001009138-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| EP-1049700-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999064041-A1 | MULTIBINDING AGENTS THAT MODULATE NMDA RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999037651-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENIUM PHARMACEUTICALS, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| US-5350852-A | Neurokinin A receptor antagonist | SANOFI (FR) | 1994-09-27 | — | — | US | disclosed |
| US-5236921-A | Administrering for treatment of neutrogenic inflammation of the respiratory trart | SANOFI (FR) | 1993-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | MIF, MMP12, SLC11A2 | DRD2 4337/4885ESR2 3986/4885ESR1 4439/4885 |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | DRD2 3118/4885ESR2 1898/4885ESR1 4357/4885 |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | DRD2 3118/4885ESR2 1898/4885ESR1 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.